Bliss GVS Pharma intimated stock exchanges about its upcoming board meeting on May 12, 2026.
The board will consider FY26 audited standalone and consolidated financial results and statements.
The board will also recommend a final dividend for FY26, subject to approval.
The trading window closure for designated persons remains effective until 48 hours post-results announcement.